Enterprise Value

195.2M

Cash

41.81M

Avg Qtr Burn

-3.569M

Short % of Float

10.01%

Insider Ownership

34.92%

Institutional Own.

13.84%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPro1595 (XPro™) Details
Alzheimer's disease

Phase 2

Data readout

INB03 + trastuzumab-deruxtecan Details
Cancer, Pancreatic cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer , Gastric cancer

Phase 2

Update

XPro1595 (XPro™) (pegipanermin fr) Details
Major depressive disorder, Mental health, Treatment Resistant Depression

Phase 2

Update

INKmune™ Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Phase 1/2

Data readout

INKmune™ Details
Cancer, Myelodysplastic syndrome, Acute myeloid leukemia

Phase 1

Data readout

LIVNate Details
NASH-induced significant or severe fibrosis, Liver disease

Failed

Discontinued

Failed

Discontinued